CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 68, Issue 9, 2012, Pages 1267-1274

  Gawroñska Szklarz, Barbara ^a   Adamiak Giera, Urszula ^a   Wyska, Elzbieta ^b   Kurzawski, Mateusz ^a   Gornik, Wanda ^a   Kaldonska, Maria ^a   Drozdzik, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

CYP2C19 polymorphism; Pantoprazole; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C19; PANTOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CYP2C19 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GENE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; FEMALE; HALF-LIFE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHENOTYPE; POLAND; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 84866632585     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1252-3     Document Type: Article

References (23)

1. Wilkinson GR, Guengerich FP, Branch RA (1995) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53-76
2. De Morais SM,Wilkinson GR, Blaisdell J, Nakamura K, Meyer U, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422
3. Goldstein JA, de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299
4. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113
5. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TH, Halling J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, Brosen K, Ingelman-Sundberg M (2010) Linkage disequilibrium between the CYP2C1917 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 66:1199-1205
6. Tanaka M, Ohkubo T, Otani K, Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Ishizaki T (2001) Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 69:108-113
7. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, Kuipers EJ, Geus WP (2008) Effect of CYP2C1922 and17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 65:752-760
8. Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, VAN Schaik RH, Kuipers EJ, Kooiman JC, Geus WP (2010) A comparison of theacid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 31:150-159
9. Kearns GL, Leeder JS, Gaedigk A (2010) Impact of the CYP2C19 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 38:894-897
10. Gawroñska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Droÿdzik M (2010) Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol 66:681-687
11. Storms ML, Stewart JT (2002) Development of a reversed-phase liquid chromatographic method for the analysis of amoxicillin, metronidazole and pantoprazole in human plasma using solidphase extraction. J Liquid Chromatogr Rel Tech 25:2433-2443
12. Rowland M, Tozer TN (1989) Clinical pharmacokinetics: concepts and applications, 2nd edn. Lea and Febiger, Philadelphia
13. NONMEM Users Guides, (1989-98). Beal SL, Sheiner LB (eds) Icon Development Solutions, Ellicott City, MD
14. Zhao F,Wang J, Yang Y,Wang X, Shi R, Xu Z, Huang Z, Zhang G (2008) Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 13:532-541
15. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935-951
16. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158-168
17. Cheer SM, Prakash A, Faulds D, Lamb HM (2003) Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 63:101-133
18. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A (2010) Cytochrome 2 C19allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512-518
19. Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC, Bertilsson L, Ingelman-SundbergM, Eliasson E (2008) Kinetics of omeprazole and escitalopram in relation to the CYP2C19 allele in healthy subjects. Eur J Clin Pharmacol 64:1175-1179
20. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman- Sundberg M, Eliasson E, Bertilsson L (2006) Increased omeprazole metabolism in carriers of the CYP2C19 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65:767-774
21. Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ (2006) Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 62:107-112
22. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492
23. Kurzawski M, Gawroñska-Szklarz B, Wrzeæniewska J, Siuda A, Starzyñska T, Droÿdzik M (2006) Effect of CYP2C19 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877-880